HBM9161 Injection (680mg) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
11重症筋無力症2

11. 重症筋無力症


臨床試験数 : 332 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05332210
(ClinicalTrials.gov)
June 30, 20226/4/2022Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisA Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisMyasthenia GravisDrug: HBM9161 Injection (680mg)Harbour BioMed (Guangzhou) Co. Ltd.NULLRecruiting18 YearsN/AAll144Phase 3China
2NCT05039190
(ClinicalTrials.gov)
September 25, 202129/8/2021Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG PatientsA Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 Study to Evaluate the Efficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisMyasthenia GravisDrug: HBM9161 Injection (680mg);Drug: PlaceboHarbour BioMed (Guangzhou) Co. Ltd.NULLCompleted18 Years99 YearsAll132Phase 3China